Actively Recruiting
A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria
Led by Menzies School of Health Research · Updated on 2025-07-18
1090
Participants Needed
4
Research Sites
146 weeks
Total Duration
On this page
Sponsors
M
Menzies School of Health Research
Lead Sponsor
U
University of Melbourne
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to assess the efficacy and safety or a revised weight band tafenoquine dose in vivax malaria patients. The main question\[s\] it aims to answer are: * is a revised weight-based TQ regimen (TQRevised: target dose 7.5mg/kg) non-inferior to high dose primaquine (7mg/kg over 7 days) * is a revised weight-based TQ regimen (TQRevised: target dose 7.5mg/kg) superior to fixed dose tafenoquine (300mg) * is the tolerability and safety of TQRevised acceptable * is TQRevised acceptable and feasible Participants will receive a tafenoquine target dose 7.5mg/kg in weight bands. Researchers will compare this to patients receiving a fixed dose tafenoquine and high dose primaquine to see if safe and effective.
CONDITIONS
Official Title
A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria
Who Can Participate
Eligibility Criteria
You may qualify if you...
- P. vivax peripheral parasitaemia (mono-infection)
- G6PD normal status (G6PD activity 970% of the adjusted male median as determined by the Standard G6PD (SDBioline, ROK))
- Fever (temperature 937.5�B0C) or history of fever in the preceding 48 hours
- Written informed consent
- Living in the study area and willing to be followed for six months
You will not qualify if you...
- Danger signs or symptoms of severe malaria
- Anaemia (defined as Hb <8g/dl)
- Pregnant or lactating females
- Regular use of drugs with haemolytic potential
- Known hypersensitivity to any of the study drugs
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Dr Marcus Lacerda
Manaus, Brazil
Actively Recruiting
2
Arba Minch General Hospital
Arba Minch, Ethiopia
Actively Recruiting
3
Puskesmas Hanura
Hanura, Indonesia
Not Yet Recruiting
4
Dr Moses Laman and Dr Brioni Moore
Alexishafen, Papua New Guinea
Actively Recruiting
Research Team
H
Hellen Mnjala
CONTACT
K
kamala K Thriemer
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here